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ABSTRACT 
Background: The novel coronavirus pneumonia has attracted considerable attention from the international community. 
With the spread of outbreaks around the world, the WHO characterized COVID-19 as a pandemic.  
Methods: Relevant studies in PubMed were searched from January 1, 2020 to April 12, 2020, using the following search 
strategy: (“novel coronavirus pneumonia” OR “severe acute respiratory syndrome coronavirus 2” OR “coronavirus disease 
2019” OR “COVID-19” OR “novel coronavirus pneumonia”) AND (“ophthalmology” OR “ophthalmologist” OR “eye” OR 
“conjunctiva” OR “conjunctivitis” OR “corneal” OR “keratitis”).  
Results: SARS-CoV-2 can spread through aerosol and is detected in tears of patients with COVID-19 infection. Notably, 
some infected patients had conjunctivitis, and conjunctivitis was the first symptom in some patients later diagnosed to 
have COVID-19 infection. This would increase the risk for ophthalmologists through inpatient consultations or regular 
clinical practice. When dealing with seemingly regular ophthalmic patients, the vigilance of ophthalmologists and 
associated staff tends to be reduced.  
Conclusion: Ophthalmologists must continuously update their knowledge regarding COVID-19 and take effective measures 
to prevent COVID-19 transmission. 
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INTRODUCTION
The outbreak of a novel coronavirus (CoV) in Wuhan City, 
Hubei Province, China, has become an international 
public-health emergency [1]. On February 11, 2020, the 
International Committee of Viral Taxonomy gave the 
name of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), and the pneumonia it causes as coronavirus 
disease 2019 (COVID-19) by the World Health 
Organization (WHO) [2]. Up to April 12, 2020, the number 
of confirmed patients had reached 1.70 million 
worldwide, and the total number of deaths was 105,952. 
The infection was spread from China to the United States 
of America (the US). The number of new patients outside 
China far exceeded those reported inside China, especially 
in the US, Spain and Italy [3]. Finally, the WHO 
characterized COVID-19 as a pandemic on March 11 [1]. 
SARS-CoV-2 is a new type of betacoronavirus, it is heat and 
ultraviolet sensitive and can be inactivated after 30 min at 
56°C. Besides, 75% ethanol, chlorine-containing 
disinfectant, ether, peracetic acid, and chloroform can 
deactivate the virus. SARS-CoV-2 is believed to be 
homologous with a bat coronavirus, and some studies 
suggest that pangolins and minks may be intermediate 
Review Article 
 
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(3)  
165 COVID-19 IN OPHTHALMOLOGY PRACTICE 
virus hosts [4, 5]. The primary source of epidemic 
transmission is the infected patient; asymptomatic 
patients also contribute but are not the primary infection 
source [6-8]. A recent report showed that some patients 
are detected to have positive results even after 8 days of 
symptom relief [9]. The main transmission routes include 
respiratory droplets and contact with skin or body 
fluids/secretions containing the virus. WHO announced 
that SARS-CoV-2 can survive for eight hours in the air and 
spread through aerosol [10]. RNA of SARS-CoV-2 has also 
been found in stool samples of infected patients, which 
increase the possibility of transmission through the 
fecal/oral route [11]. Though a recent study detected 
viable SARS-CoV-2 in aerosols up to 3 hours post-
aerosolization [12], the non-ventilated environment for 
the experiment might not have reflected how viruses 
behave under real-life conditions. This study also found 
that the virus can survive for 4 hours on copper, 24 hours 
on cardboard, and 2–3 days on plastic or stainless steel 
[12], which indicated that handwashing and cleaning 
surfaces and materials contaminated by secretions of 
COVID-19 patients is important. 
Infected patients often have fever, as well as respiratory 
symptoms, like cough and shortness of breath; some 
patients are presented with diarrhea shortly after 
infection. Pneumonia can also be a presentation in severe 
forms of the infection. Symptoms may occur as early as 2–
14 days after exposure [13]. The average incubation 
period of SARS-CoV-2 is 5–7 days. More than 97% of 
patients develop symptoms within 11.5 days of exposure, 
which supports the current 14-day quarantine 
recommendations. Very few cases have lasted for 24 days 
[6]. 
COVID-19 is the third acute respiratory infectious disease 
caused by a cross-species coronavirus arisen in the past 20 
years [7]. The first was severe acute respiratory syndrome 
(SARS) caused by the severe acute respiratory syndrome 
coronavirus (SARS-CoV), began in 2003 in Guangdong 
Province, China [14]. The second was the Middle East 
respiratory syndrome (MERS) caused by the Middle East 
respiratory syndrome coronavirus (MERS-CoV), which 
started in Saudi Arabia in 2012 [15]. During the SARS 
epidemic, about one-fifth of infected patients were 
medical workers. As of February 24, 2020, data from an 
official news source showed that 3,387 healthcare 
workers were infected with SARS-CoV-2 [16]. As of March 
27, there were 6,205 and 9,444 medical workers 
diagnosed with COVID-19 in Italy and Spain, respectively 
[17]. More importantly, several recent studies have shown 
that the virus might invade the human body through the 
conjunctiva and cause conjunctivitis [18-21]. Although this 
phenomenon is currently uncommon in infected patients, 
it could increase the likelihood of infected patients visiting 
ophthalmologists [22, 23]. To our knowledge, at least six 
ophthalmologists have been infected with COVID-19 in 
the original outbreak area of Wuhan City, China; three 
died, and the other three recovered (personal 
communication from Dr. Wei-Jing Yin, Director of the 
Editorial Office, Chinese Journal of Experimental 
Ophthalmology). Most ophthalmologists were not on the 
front lines of dealing with this outbreak in China, but they 
still had risks of infection and transmission for various 
reasons (e.g., consultation of infected patients, 
ophthalmic emergency in a hospital environment). 
Ophthalmologists should strictly follow measures to 
control the infection’s spread when facing patients with 
infection or suspected infection for such reasons. This 
review paper aimed to provide background knowledge of 
COVID-19 and some suggestions for ophthalmologists and 
associated researchers on how to understand and deal 
with this problem. 
 
METHODS 
Relevant studies in PubMed were searched from January 
1, 2020 to April 12, 2020, using the following search terms: 
(“novel coronavirus pneumonia” OR “severe acute 
respiratory syndrome coronavirus 2” OR “coronavirus 
disease 2019” OR “COVID-19” 
novel coronavirus pneumonia) AND (“ophthalmology” OR 
“ophthalmologist” OR “eye” OR “conjunctiva” OR 
“conjunctivitis” OR “corneal” OR “keratitis”). In addition, 
we searched and referenced the official website of the 
World Health Organization, Centers for Disease Control 
and Prevention, The American Academy of 
Ophthalmology, Eye Bank Association of America and 
National Health Commission of the People's Republic of 
China. 
 
RESULTS AND DISSCUSSION 
COVID-19 AND OCULAR INFECTION 
CoVs belong to the category of respiratory viruses, which 
mainly infect the respiratory tract, and of which 
respiratory diseases are the main manifestations 
threatening public health. A study showed that some 
respiratory viruses also bind to the ocular surface and 
cause conjunctivitis in humans [24]. SARS-CoV is a 
respiratory virus that mainly infects the respiratory tract. 
It is primarily transmitted through direct or indirect 
contact with the respiratory-tract epithelium [14]. A 
study suggested that during the SARS epidemic, the risk of 
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transmission from infected patients to medical staff 
increased due to lack of goggles [25]. SARS-CoV was 
detected in tears in three early-stage cases [26]. In animal 
models (including mice, cats, rats, and pigs), ocular 
diseases can be caused after SARS-CoV is inoculated in the 
eye, mouth, or nose [27-29]. However, some studies did 
not detect SARS-CoV in tears or conjunctival samples from 
SARS patients. No significant ocular abnormalities, or 
deterioration or acceleration of the original ocular 
disease, were found in SARS patients [30, 31]. Despite 
these inconsistent findings, the conjunctiva cannot be 
excluded as a potential invasive pathway for SARS-CoV-2. 
Like SARS-CoV, SARS-CoV-2 enters respiratory epithelial 
cells by binding to angiotensin-converting enzyme 2 
(ACE2) on the cell surface through the spike (S) protein on 
the virus’s surface and then replicates in the lung [32]. 
ACE2 messenger RNA (mRNA) and its enzyme are 
expressed in human eyes [33]. Further studies show that 
ACE2 is mainly expressed in the eye’s posterior segment 
(including retinal nerve cells and retinal pigment epithelial 
cells) and exists in the aqueous humor [34, 35]. However, 
the characteristics of ACE2 expression in human corneal 
and conjunctival epithelial cells are not well-documented 
[36, 37]. Recent studies found that some COVID-19 
patients had conjunctivitis; in some patients, 
conjunctivitis was the first symptom [20, 38]. Another 
study indicated that 2 of 27 COVID-19 patients had 
positive PCR results for SARS-CoV-2 in conjunctival-sac 
swab tests, but they did not have conjunctivitis [39]. 
Therefore, it is unclear whether the conjunctiva could be 
a locus of viral invasion and/or replication. It is crucial for 
healthcare workers to take various precautions according 
to the WHO guidelines that prevent the infection 
transmission [40, 41]. When in contact with patients 
diagnosed or suspected to have COVID-19, they should 
wear goggles and face masks to prevent possible 
transmission through facial skin, the nasal cavity, or the 
ocular surface. 
THE OPHTHALMOLOGIST’S ADAPTATION TO THE CURRENT 
COVID-19 PANDEMIC 
For Patients with Confirmed Diagnosis in the Hospital 
and/or Suspected Patients in Quarantine 
In clinical practice, ophthalmologists might visit COVID-19 
patients. The main reason is that some COVID-19 patients 
have ocular discomforts like dry eye and conjunctivitis, 
some develop ocular diseases (e.g., glaucoma) before 
infection that require an ophthalmologist visit, and 
occasionally an ocular emergency such as sudden vision 
loss [38, 42]. When these situations happen, the following 
specific measures are recommended for better preventing 
primary transmission of SARS-CoV-2 to protect patients, 
families and medical staff [43]. 
General Precautions 
To reduce the transmission between patients, 
ophthalmologists should practice the following common 
precautions [44]: 1) Handwashing: Wash hands before 
and after contact with infected patients. 2) Wearing 
gloves: Avoid contacting patient’s blood, body fluids, 
secretions and personal possessions. 3)  Medical waste 
should be put into a double-layer medical waste bag, and 
seal the bag with a gooseneck ties, and spray the waste 
bag by chlorine-containing disinfectant (1000 milligrams 
per liter). 
Droplet Transmission Precautions 
At present, SARS-CoV-2 main transmission modes are 
both droplet inhalation and contact. When the pathogen 
is transmitted from the infected or suspected infected 
person through the more than 5 micrometre droplets 
produced by coughing, sneezing, or speaking, the 
corresponding protection measures should be taken [41]. 
Specifically: 1) Wear N95 masks when working close to 
infected or suspected infected patients. 2) Try to reduce 
the transport of inpatients with SARS-CoV-2 infection as 
much as possible. Patients should wear masks during 
transfer. 3) Try to avoid working close by the patient, such 
as slit-lamp or fundoscopy examination. 
Contact Transmission Precautions 
Contact is the other main transmission route of SARS-CoV-
2. Most contact transmission occurs during clinical 
examination. In clinical practice, contact with the patient’s 
eyes and tears is almost inevitable. Transmission of 
pathogens can occur when contaminated hands touch the 
face, the eyes, or open wounds. Main measures to be 
taken for ophthalmologists when visiting an infected or 
suspected patients are as follows [43, 45]: 1) Wear sterile 
gloves and a disposable gown before entering the 
infectious patient’s ward, remove the gloves and the gown 
and wash hands with disinfectant immediately before 
leaving the patient’s room, and ensure there is no further 
contact with the patient’s environment and possessions to 
reduce the possibility of contamination. 2) Clean and 
disinfect equipment and properly dispose medical waste 
after the examination. This guideline considers the 
possibility that the virus could remain on various 
ophthalmic equipment (including slit lamp, Goldmann 
applanation tonometer, optical-coherence tomography 
(OCT), ophthalmic ultrasound equipment and trial frame) 
after an infected patient is examined. Thus, all ophthalmic 
equipment should be cleaned and disinfected (e.g., wiped 
with 75% ethanol or 3% hydrogen peroxide on a cotton 
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ball) to ensure the safety for next patients. Equipment and 
instruments used by infected or suspected patients should 
be sterilized according to the Regulation of Disinfection 
Technique in Healthcare Settings [46]. 
For Regular Outpatient Clinic 
Preliminary clinical research has shown that some COVID-
19 patients manifest conjunctivitis, which might be a 
symptom of this disease [18, 38]. More importantly, an 
experimental study confirmed that rhesus macaques can 
be infected with SARS-CoV-2 via the conjunctiva with a 
relatively independent transmission route. Viral particles 
in tears and other eye secretions might enter respiratory 
tract through the nasolacrimal duct, or enter the digestive 
system after being swallowed [21, 35]. This means that 
ophthalmologists should take strict measures to prevent 
the possibility of transmission through the ocular surface. 
Therefore, they should pay close attention to the 
following issues [40, 47]: 1) travel history of patients to the 
US, Italy, Spain, Iran and other areas with high number of 
infected patients; or patients with family members that 
come back from these areas recently; 2) whether patients 
have respiratory symptoms; and 3) whether they have 
signs of conjunctivitis, such as conjunctival congestion and 
tearing. Patients who meet the above criteria should be 
examined for COVID-19. 
The US and the Europe are now the outbreak centers. 
Ophthalmologists in these areas should take stricter 
measures to prevent the spread of infection. We 
recommend adoption of the following measures based on 
the WHO guidelines and recent published articles [23, 41]: 
(1) Pre-examination and triage area should be set up to 
perform preliminary screening of patients. (2) Avoid 
examinations as much as possible. When an examination 
is unavoidable, a transparent breath shield can be 
installed on the slit-lamp microscope to protect both 
healthcare workers and patients from droplet 
transmission occurring during the examination. (3) Direct-
contact examination of the ocular surface, as in a corneal-
perception examination or Schirmer’s test for tear 
production, should be minimized as much as possible [48]. 
An indirect fundus ophthalmoscope or fundus 
angiography equipment could be used instead of a close-
contact direct ophthalmoscope for patients who need a 
fundus examination. When necessary to measure the 
patient’s intraocular pressure, a non-contact tonometer is 
recommended. Phenol red cotton thread or test strips for 
measuring tear secretion should be handled in strict 
accordance with dangerous medical-waste regulations. 
(4) Both doctors and patients should wear masks, and 
ophthalmologists should wear goggles. (5) 
Ophthalmologists and their associates should wash their 
hands between examinations of different patients to 
prevent cross-transmission. (6) For instruments (e.g., 
Goldmann applanation tonometer, gonioscope) directly 
contacting the ocular surface, “one patient, one 
disinfection” measures should be followed. Using a 70% 
alcohol solution can effectively disinfect tonometer [47]. 
(7) Rooms, office furniture and other ophthalmic 
instruments where patients put their hands or faces, 
should be thoroughly disinfected with alcohol- and 
bleach-based disinfectants after each patient encounter 
[47]. Disinfectants specific to COVID-19 recommended by 
the US Centers for Disease Control and Prevention (CDC) 
are diluted household bleach, > 70% alcohol solutions, and 
common US Environmental Protection Agency (EPA)–
registered household disinfectants [49]. (8) When 
surfaces are cleaned and disinfected, disposable gloves 
should be worn and discarded after use. 
For Ophthalmic Operating Rooms during the Outbreak 
The recommended measures are as follows [50]: (1) For 
nonemergency occasions, surgery in severely epidemic 
areas should be postponed. If it is necessary to perform an 
emergency operation, the suspected or confirmed 
infected patient should be scheduled as the last one, and 
the operation should be performed in an operating room 
with a negative-pressure environment and proper 
ventilation [51]. (2) Medical staff should wear medical-
grade protective masks and goggles. (3) During the 
pandemic, personnel flow during the operation should be 
reduced. (4) In the operating room, appropriate humidity 
(<68%) and temperature control should be maintained. (5) 
A portable industrial-grade, high-efficiency particle barrier 
filter should be used to remove air pollutants quickly. (6) 
The following tertiary-prevention measures should be 
taken: (a) Respiratory protectors offering high ingress 
protection should be worn in the operating room, and (b) 
unnecessary personnel should be prohibited from 
entering the operating room. 
CONFIRMED AND SUSPECTED COVID-19 INFECTIONS ARE 
EXCLUSION CRITERIA FOR CORNEAL DONATION 
Keratoplasty is one of the most important measures for 
restoring corneal blindness. However, any organ or tissue 
transplantation has the risk of transmitting infectious 
diseases. Therefore, the eye bank system sets strict 
medical standards for screening potential donors [52]. 
During the 2003 SARS epidemic, one study found a large 
number of viral particles in many tissues and cell types, 
such as lymphocytes, monocytes, respiratory epithelial 
cells, intestinal mucosa, distal renal epithelial cells, 
neurons in the brain, and macrophages in different organs 
of infected patients [53]. Although, there is no evidence of 
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SARS-CoV-2 virus particles in corneal tissue, and no clinical 
studies and/or case reports of transmission to recipients 
after corneal transplantation from donors with COVID-19, 
this possibility cannot be excluded. Given the similarities 
and high risk for transmission of SARS-CoV-2, the authors 
recommend the following [54]: (1) Corneal-transplant 
programs should be postponed during the outbreak, if 
possible. (2) Infected patients should not be used as 
potential donors even in emergency transplant situations. 
(3) Donors carrying the SARS-CoV-2 virus should be 
included in the eye bank medical-exclusion standards. (4) 
Before transplantation, it should be clear whether 
potential donors have a history of (a) confirmed or 
suspected COVID-19 infection and (b) respiratory-tract 
symptoms of suspected viral origin during the 14 days 
preceding death. Strict SARS-CoV-2 virus detection should 
be performed for donors. (5) Eye bank staff should obtain 
donors’ recent travel history to epidemic areas and chest 
X-rays or computed-tomography (CT) image records to the 
greatest extent possible. 
COLLECTION, PROCESSING AND TRANSPORT OF OCULAR 
SPECIMENS 
For scientific research, diagnosis, and other special needs 
(e.g., detecting viruses or certain components in tears 
from confirmed or suspected infected persons), some eye 
samples or specimens must be collected. However, the 
results are usually affected by many factors, such as time, 
the surrounding collection environment, the amount of 
sample, the method of preservation, and the process of 
transport. It is critical to follow the established standards 
for the laboratory process [55]. In addition, considering 
the disease severity and its ease of transmission, all 
manipulations involving samples should follow strict 
biosafety procedures. Notably, when packing, mailing, 
and transporting specimens, the regulations for 
dangerous goods should be followed [56]. 
When detecting SARS-CoV-2 via reverse-transcription 
polymerase chain reaction (RT-PCR), special attention 
should be paid to the following points [55]: (1) use 
synthetic-fiber swabs instead of wooden swabs, which 
contain components such as calcium alginate that might 
inactivate some viruses and inhibit certain reactions 
during PCR testing; (2) prevent degradation of RNA in 
samples using RNAase-free water and dithiothreitol; (3) 
put the sample swab into a sterile tube containing 2–3 ml 
culture medium for virus transport; (4) change gloves 
when handling different patient samples to avoid cross-
contamination; (5) perform all sample handling in a cold 
environment; and (6) store the sample at −70° C as soon 
as possible and transport it in dry ice. 
 
Table 1. A Summary of Main Recommendations Proposed to Face 
COVID-19 in Ophthalmology Practice. 
How to Face COVID-19 in Ophthalmology Practice 
 
General Precautions 
 
1) Handwashing before and after contact with patients.  
2) Wear gloves to avoid contacting body fluids and secretions.  
3) Proper disposing of COVID-19 medical waste. 
Droplet Transmission Precautions 
 
1) Wear N95 masks when working close to patients.  
2) Reduce transport of infected cases as much as possible.  
3) Avoid working close as much as possible. 
4) Patients should wear masks during transfer.  
Contact Transmission Precautions 
 
1) Wear sterile gloves and a disposable gown before entering the 
infectious ward. 
2) Remove the gloves and gown and wash hands with disinfectant 
before leaving the patient’s room.  
3) Clean and disinfect all ophthalmic equipment (e.g., wiped with 75% 
ethanol or 3% hydrogen peroxide on a cotton ball) and properly 
dispose medical waste. 
For Regular Outpatient Clinic 
 
1) Take recent travel history of patients or their associates to high risk 
areas.  
2) Ask for respiratory symptoms. 
3) Ask for signs of conjunctivitis. 
4) Set up triage area to perform preliminary screening.  
5) Avoid close examinations as much as possible. Install breath shield 
on the slit-lamp. 
6) Minimize direct-contact examination of the ocular surface as much 
as possible. Use indirect fundus ophthalmoscope or fundus 
angiography, instead. 
7) Measure intraocular pressure using a non-contact tonometer. 
8) Used test strips for measuring tear secretion should be handled 
with dangerous medical-waste regulations.  
9) “one patient, one disinfection” measures should be followed.   
10) Rooms, office furniture and ophthalmic instruments should be 
thoroughly disinfected. 
11) When surfaces are disinfected, disposable gloves should be worn 
and discarded after use. 
For Ophthalmic Operating Rooms 
 
1) In nonemergency occasions, surgery should be postponed.  
2) If surgery is emergency, the suspected or confirmed case should 
be scheduled as the last one, in a room with a negative-pressure 
environment and proper ventilation. 
2) Medical staff should wear medical-grade protective masks and 
goggles.  
3) Personnel flow during the operation should be reduced.  
4) Appropriate humidity (<68%) and temperature control should be 
maintained.  
5) A portable industrial-grade, high-efficiency particle barrier filter 
should be used. 
6) Respiratory protectors offering high ingress protection should be 
worn in the operating room, and unnecessary personnel should not 
enter the operating room. 
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CONCLUSION 
The main recommendations have been summarised in 
Table 1. Currently, the number of patients with COVID-19 
infection is increasing worldwide. On the other hand, the 
virus could be potentially transmitted through the 
conjunctiva. Therefore, ophthalmologists should take 
strict measures in clinical practice to prevent the 
possibility of transmission through the ocular surface. 
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